EJMI. 2023; 7(2): 153-161 | DOI: 10.14744/ejmi.2023.22720

Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data

Atakan Topcu¹, Mehmet Besiroglu¹, Muhammed Mustafa Atci², Saban Secmeler², Murat Ayhan³, Metin Ozkan⁴, Oktay Bozkurt⁴, Zuhat Urakci⁵, Seval Ay⁶, Caglayan Geredeli², Ayse Irem Yasin¹, Ozge Pasin⁷, Haci Mehmet Turk^1
1Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Türkiye, ²Department of Medical Oncology, University of Health Sciences, Prof. Dr Cemil Tascioglu City Hospital, Istanbul, Türkiye, ³Department of Medical Oncology, University of Health Sciences, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Türkiye, ⁴Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, Türkiye, ⁵Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakir, Türkiye, ⁶Department of Medical Oncology, Medeniyet University Faculty of Medicine, Istanbul, Türkiye, ⁷Department of Biostatistics, Bezmialem Vakif University Faculty of Medicine, Istanbul, Türkiye Department of Biostatistics, Bezmialem Vakif University Faculty of Medicine, Istanbul, Türkiye

Objectives: To compare the second-line treatments on survival after trastuzumab failure in HER2-positive metastatic gastric cancer. Methods: We retrospectively included 57 patients. Of whom, 32 (56%) received paclitaxel, whereas 25 (44%) received 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI). We analyzed the patient characteristics, and survival outcomes of the second-line treatment. Results: The median PFS was 3.5 months in the paclitaxel-group and 4.8 months in the FOLFIRI-group (p=0.569). The median overall survival (OS) was 6.0 months in paclitaxel-group and 11.0 months in FOLFIRI-group (p=0.410). FOLFIRI provided a significant OS advantage over paclitaxel in patients with grade 3 tumors or who did not have an objective first-line treatment response. Conclusion: FOLFIRI may be recommended as a preferred option over paclitaxel in patients with these identified risk factors. Keywords: FOLFIRI, Gastric cancer, HER2, paclitaxel, second-line therapy, trastuzumab failure

---

Cite This Article

Topcu A, Besiroglu M, Atci M, Secmeler S, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin A, Pasin O, Turk H. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI. 2023; 7(2): 153-161

Corresponding Author: Atakan Topcu

Full Text PDF PDF Download